SCHEMBL26501696

SCHEMBL26501696

Cc1ccc(CC(=O)Nc2ccc(C(Cl)Cl)cc2)nn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.39
GAA P10253 4/20 0.39
MAPT P10636 4/20 0.39
TP53 P04637 2/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 3/20 0.37
TSHR P16473 1/20 0.37
NPC1 O15118 2/20 0.36
LMNA P02545 1/20 0.36
WNT3A P56704 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
PTPN1 P18031 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26501545 0.88 SMN1; SMN2 (0.51) SMN1; SMN2MAPTTP53ALDH1A1POLB
SCHEMBL26501695 0.86 SMN1; SMN2 (0.40) SMN1; SMN2GAAMAPTTP53KDM4E
SCHEMBL26501699 0.84 TSHR (0.44) SMN1; SMN2GAAMAPTTP53ALDH1A1
SCHEMBL26501698 0.83 TSHR (0.43) SMN1; SMN2GAAMAPTTP53ALDH1A1
SCHEMBL26501697 0.82 RORC (0.41) SMN1; SMN2GAAMAPTTP53KDM4E
SCHEMBL26501693 0.80 MAPT (0.44) SMN1; SMN2MAPTKDM4EALDH1A1RAB9A
SCHEMBL26501786 0.79 RAB9A (0.36) SMN1; SMN2MAPTKDM4EALDH1A1POLB
SCHEMBL26501671 0.78 CNR2 (0.33) TDP1LMNA
SCHEMBL26501700 0.75 PTPN1 (0.40) SMN1; SMN2GAAMAPTKDM4EALDH1A1
SCHEMBL27395185 0.73 POLB (0.36) SMN1; SMN2GAAMAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321092-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321092-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR HMGCR, GCDH, CYP11A1 SMN1; SMN2 1609/4885GAA 101/4885MAPT 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.